Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Authors
Keywords
RECIST, Early efficacy metrics, Early tumor size changes, Cut-off values, Immunotherapy trials
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-02-09
DOI
10.1186/s40425-019-0513-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
- (2018) Sirisha L. Mushti et al. CLINICAL CANCER RESEARCH
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials
- (2017) Julien Taieb et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials
- (2017) Gideon M. Blumenthal et al. JAMA Oncology
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- A simple method to estimate the time-dependent receiver operating characteristic curve and the area under the curve with right censored data
- (2016) Liang Li et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
- (2015) Volker Heinemann et al. EUROPEAN JOURNAL OF CANCER
- Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods
- (2015) Ming-Wen An et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
- (2015) Ming-Wen An et al. JNCI-Journal of the National Cancer Institute
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
- (2015) Ming-Wen An et al. JNCI-Journal of the National Cancer Institute
- 10% Tumor Diameter Shrinkage on the First Follow-Up Computed Tomography Predicts Clinical Outcome in Patients With Advanced Renal Cell Carcinoma Treated With Angiogenesis Inhibitors: A Follow-Up Validation Study
- (2014) K. M. Krajewski et al. ONCOLOGIST
- Use of Early Tumor Shrinkage to Predict Long-Term Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
- (2013) Hubert Piessevaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer
- (2013) Laurent Claret et al. JOURNAL OF CLINICAL ONCOLOGY
- Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
- (2013) Paul Blanche et al. STATISTICS IN MEDICINE
- Designing exploratory cancer trials using change in tumour size as primary endpoint
- (2012) Thomas Jaki et al. STATISTICS IN MEDICINE
- The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy
- (2011) C. Suzuki et al. ANNALS OF ONCOLOGY
- Comparison of Continuous versus Categorical Tumor Measurement-Based Metrics to Predict Overall Survival in Cancer Treatment Trials
- (2011) M.-W. An et al. CLINICAL CANCER RESEARCH
- Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
- (2011) Katherine M. Krajewski et al. EUROPEAN UROLOGY
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now